Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5363 + Docetaxel + Prednisolone in mCRPC (ProCAID)
NCT02121639Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jan 2014
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capivasertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University Hospital Southampton NHS Foundation Trust. Started Jan 2014; status: completed.
02
Drugs
capivasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02121639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121639.